{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T19:28:04Z","timestamp":1675625284442},"reference-count":144,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2010,6,12]],"date-time":"2010-06-12T00:00:00Z","timestamp":1276300800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HNO"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1007\/s00106-010-2118-6","type":"journal-article","created":{"date-parts":[[2010,6,10]],"date-time":"2010-06-10T14:50:01Z","timestamp":1276181401000},"page":"778-790","source":"Crossref","is-referenced-by-count":5,"title":["Prophylaktische und therapeutische Vakzinen gegen humane Papillomviren"],"prefix":"10.1007","volume":"58","author":[{"given":"A.E.","family":"Albers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.K.","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.P.","family":"Klussmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.M.","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,6,12]]},"reference":[{"key":"2118_CR1","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1099\/0022-1317-50-5-468","volume":"50","author":"Aaltonen","year":"2001","unstructured":"Aaltonen LM, Auvinen E, Dillner J et al (2001) Poor antibody response against human papillomavirus in adult-onset laryngeal papillomatosis. J Med Microbiol 50:468\u2013471","journal-title":"J Med Microbiol"},{"key":"2118_CR2","doi-asserted-by":"crossref","first-page":"11146","DOI":"10.1158\/0008-5472.CAN-05-0772","volume":"65","author":"Albers","year":"2005","unstructured":"Albers A, Abe K, Hunt J et al (2005) Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck. Cancer Res 65:11146\u201311155","journal-title":"Cancer Res"},{"key":"2118_CR3","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1007\/s00262-005-0670-9","volume":"54","author":"Albers","year":"2005","unstructured":"Albers AE, Ferris RL, Kim GG et al (2005) Immune responses to p53 in patients with cancer: enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites. Cancer Immunol Immunother 54:1072\u20131081","journal-title":"Cancer Immunol Immunother"},{"key":"2118_CR4","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1159\/000214923","volume":"12","author":"Albers","year":"2009","unstructured":"Albers A, Kaufmann AM (2009) Therapeutic human papillomavirus vaccination. Public Health Genomics 12:331\u2013342","journal-title":"Public Health Genomics"},{"key":"2118_CR5","unstructured":"AWMF-Online (o J) Impfpr\u00e4vention HPV-assoziierter Neoplasien. http:\/\/www.uni-duesseldorf.de\/AWMF\/ll\/082\u2013002.htm"},{"key":"2118_CR6","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ajog.2007.09.001","volume":"198","author":"Barr","year":"2008","unstructured":"Barr E, Gause CK, Bautista OM et al (2008) Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of north American women. Am J Obstet Gynecol 198:261, e261\u2013e211","journal-title":"Am J Obstet Gynecol"},{"key":"2118_CR7","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.jcv.2004.12.008","volume":"32","author":"Baseman","year":"2005","unstructured":"Baseman JG, Koutsky LA (2005) The epidemiology of human papillomavirus infections. J Clin Virol 32(Suppl 1):S16\u2013S24","journal-title":"J Clin Virol"},{"key":"2118_CR8","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1158\/1078-0432.CCR-07-5126","volume":"14","author":"Bergmann","year":"2008","unstructured":"Bergmann C, Strauss L, Wang Y et al (2008) T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res 14:3706\u20133715","journal-title":"Clin Cancer Res"},{"key":"2118_CR9","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/hed.20968","volume":"31","author":"Bergmann","year":"2009","unstructured":"Bergmann C, Strauss L, Wieckowski E et al (2009) Tumor-derived microvesicles in sera of patients with head and neck cancer and their role in tumor progression. Head Neck 31:371\u2013380","journal-title":"Head Neck"},{"key":"2118_CR10","doi-asserted-by":"crossref","first-page":"8865","DOI":"10.1158\/0008-5472.CAN-07-0767","volume":"67","author":"Bergmann","year":"2007","unstructured":"Bergmann C, Strauss L, Zeidler R et al (2007) Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res 67:8865\u20138873","journal-title":"Cancer Res"},{"key":"2118_CR11","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1155\/2007\/245146","volume":"23","author":"Brinkman","year":"2007","unstructured":"Brinkman JA, Hughes SH, Stone P et al (2007) Therapeutic vaccination for HPV induced cervical cancers. Dis Markers 23:337\u2013352","journal-title":"Dis Markers"},{"key":"2118_CR12","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1086\/426867","volume":"191","author":"Brown","year":"2005","unstructured":"Brown DR, Shew ML, Qadadri B et al (2005) A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis 191:182\u2013192","journal-title":"J Infect Dis"},{"key":"2118_CR13","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1086\/315498","volume":"181","author":"Carter","year":"2000","unstructured":"Carter JJ, Koutsky LA, Hughes JP et al (2000) Comparison of human papillomavirus types 16, 18 and 6 capsid antibody responses following incident infection. J Infect Dis 181:1911\u20131919","journal-title":"J Infect Dis"},{"key":"2118_CR14","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1093\/jnci\/dji186","volume":"97","author":"Castle","year":"2005","unstructured":"Castle PE, Solomon D, Schiffman M et al (2005) Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst 97:1066\u20131071","journal-title":"J Natl Cancer Inst"},{"key":"2118_CR15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/sj.bjc.6600688","volume":"88","author":"Clifford","year":"2003","unstructured":"Clifford GM, Smith JS, Plummer M et al (2003) Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 88:63\u201373","journal-title":"Br J Cancer"},{"key":"2118_CR16","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S1470-2045(05)70086-3","volume":"6","author":"Cogliano","year":"2005","unstructured":"Cogliano V, Baan R, Straif K et al (2005) Carcinogenicity of human papillomaviruses. Lancet Oncol 6:204","journal-title":"Lancet Oncol"},{"key":"2118_CR17","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1093\/ajcp\/102.6.768","volume":"102","author":"Coleman","year":"1994","unstructured":"Coleman N, Birley HD, Renton AM et al (1994) Immunological events in regressing genital warts. Am J Clin Pathol 102:768\u2013774","journal-title":"Am J Clin Pathol"},{"key":"2118_CR18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0964-1955(95)00060-7","volume":"32B","author":"Cruz","year":"1996","unstructured":"Cruz IB, Snijders PJ, Steenbergen RD et al (1996) Age-dependence of human papillomavirus DNA presence in oral squamous cell carcinomas. Eur J Cancer B Oral Oncol 32B:55\u201362","journal-title":"Eur J Cancer B Oral Oncol"},{"key":"2118_CR19","first-page":"472","volume":"62","author":"De","year":"2002","unstructured":"De Jong A, Van Der Burg SH, Kwappenberg KM et al (2002) Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res 62:472\u2013479","journal-title":"Cancer Res"},{"key":"2118_CR20","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1158\/0008-5472.CAN-04-0831","volume":"64","author":"De","year":"2004","unstructured":"De Jong A, Van Poelgeest MI, Van Der Hulst JM et al (2004) Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res 64:5449\u20135455","journal-title":"Cancer Res"},{"key":"2118_CR21","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1097\/00005537-200109000-00028","volume":"111","author":"Dedo","year":"2001","unstructured":"Dedo HH, Yu KC (2001) CO(2) laser treatment in 244 patients with respiratory papillomas. Laryngoscope 111:1639\u20131644","journal-title":"Laryngoscope"},{"key":"2118_CR22","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1001\/archotol.1995.01890120044008","volume":"121","author":"Derkay","year":"1995","unstructured":"Derkay CS (1995) Task force on recurrent respiratory papillomas. A preliminary report. Arch Otolaryngol Head Neck Surg 121:1386\u20131391","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"2118_CR23","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1177\/000348940511400913","volume":"114","author":"Derkay","year":"2005","unstructured":"Derkay CS, Smith RJ, McClay J et al (2005) HspE7 treatment of pediatric recurrent respiratory papillomatosis: final results of an open-label trial. Ann Otol Rhinol Laryngol 114:730\u2013737","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"2118_CR24","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/hed.21043","volume":"31","author":"Donne","year":"2009","unstructured":"Donne AJ, Hampson L, He XT et al (2009) Cidofovir induces an increase in levels of low-risk and high-risk HPV E6. Head Neck 31:893\u2013901","journal-title":"Head Neck"},{"key":"2118_CR25","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.1128\/JCM.01321-06","volume":"44","author":"Fakhry","year":"2006","unstructured":"Fakhry C, D\u2019Souza G, Sugar E et al (2006) Relationship between prevalent oral and cervical human papillomavirus infections in human immunodeficiency virus-positive and -negative women. J Clin Microbiol 44:4479\u20134485","journal-title":"J Clin Microbiol"},{"key":"2118_CR26","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1200\/JCO.2006.06.1291","volume":"24","author":"Fakhry","year":"2006","unstructured":"Fakhry C, Gillison ML (2006) Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol 24:2606\u20132611","journal-title":"J Clin Oncol"},{"key":"2118_CR27","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/jnci\/djn011","volume":"100","author":"Fakhry","year":"2008","unstructured":"Fakhry C, Westra WH, Li S et al (2008) Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100:261\u2013269","journal-title":"J Natl Cancer Inst"},{"key":"2118_CR28","first-page":"431","volume":"169","author":"Ferenczy","year":"2003","unstructured":"Ferenczy A, Coutlee F, Franco E et al (2003) Human papillomavirus and HIV coinfection and the risk of neoplasias of the lower genital tract: a review of recent developments. CMAJ 169:431\u2013434","journal-title":"CMAJ"},{"key":"2118_CR29","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1055\/s-2008-1077527","volume":"87","author":"Forster","year":"2008","unstructured":"Forster G, Boltze C, Seidel J et al (2008) Juvenile laryngeal papillomatosis \u2013 immunisation with the polyvalent vaccine gardasil. Laryngorhinootologie 87:796\u2013799","journal-title":"Laryngorhinootologie"},{"key":"2118_CR30","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1086\/315086","volume":"180","author":"Franco","year":"1999","unstructured":"Franco EL, Villa LL, Sobrinho JP et al (1999) Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 180:1415\u20131423","journal-title":"J Infect Dis"},{"key":"2118_CR31","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/j.ijporl.2006.06.006","volume":"70","author":"Freed","year":"2006","unstructured":"Freed GL, Derkay CS (2006) Prevention of recurrent respiratory papillomatosis: role of HPV vaccination. Int J Pediatr Otorhinolaryngol 70:1799\u20131803","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"2118_CR32","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/sj.cgt.7700937","volume":"13","author":"Garcia-Hernandez","year":"2006","unstructured":"Garcia-Hernandez E, Gonzalez-Sanchez JL, Andrade-Manzano A et al (2006) Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther 13:592\u2013597","journal-title":"Cancer Gene Ther"},{"key":"2118_CR33","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.otohns.2004.09.035","volume":"132","author":"Gerein","year":"2005","unstructured":"Gerein V, Rastorguev E, Gerein J et al (2005) Incidence, age at onset and potential reasons of malignant transformation in recurrent respiratory papillomatosis patients: 20\u00a0years experience. Otolaryngol Head Neck Surg 132:392\u2013394","journal-title":"Otolaryngol Head Neck Surg"},{"key":"2118_CR34","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1006\/exmp.1999.2298","volume":"68","author":"Ghim","year":"2000","unstructured":"Ghim S, Newsome J, Bell J et al (2000) Spontaneously regressing oral papillomas induce systemic antibodies that neutralize canine oral papillomavirus. Exp Mol Pathol 68:147\u2013151","journal-title":"Exp Mol Pathol"},{"key":"2118_CR35","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/jnci\/92.9.709","volume":"92","author":"Gillison","year":"2000","unstructured":"Gillison ML, Koch WM, Capone RB et al (2000) Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92:709\u2013720","journal-title":"J Natl Cancer Inst"},{"key":"2118_CR36","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/00001622-199905000-00010","volume":"11","author":"Gillison","year":"1999","unstructured":"Gillison ML, Koch WM, Shah KV (1999) Human papillomavirus in head and neck squamous cell carcinoma: are some head and neck cancers a sexually transmitted disease? Curr Opin Oncol 11:191\u2013199","journal-title":"Curr Opin Oncol"},{"key":"2118_CR37","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/S0140-6736(04)16194-1","volume":"363","author":"Gillison","year":"2004","unstructured":"Gillison ML, Lowy DR (2004) A causal role for human papillomavirus in head and neck cancer. Lancet 363:1488\u20131489","journal-title":"Lancet"},{"key":"2118_CR38","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00001622-200105000-00009","volume":"13","author":"Gillison","year":"2001","unstructured":"Gillison ML, Shah KV (2001) Human papillomavirus-associated head and neck squamous cell carcinoma: mounting evidence for an etiologic role for human papillomavirus in a subset of head and neck cancers. Curr Opin Oncol 13:183\u2013188","journal-title":"Curr Opin Oncol"},{"key":"2118_CR39","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1086\/521679","volume":"196","author":"Giuliano","year":"2007","unstructured":"Giuliano AR, Lazcano-Ponce E, Villa L et al (2007) Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine. J Infect Dis 196:1153\u20131162","journal-title":"J Infect Dis"},{"key":"2118_CR40","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1177\/000348940311200402","volume":"112","author":"Go","year":"2003","unstructured":"Go C, Schwartz MR, Donovan DT (2003) Molecular transformation of recurrent respiratory papillomatosis: viral typing and p53 overexpression. Ann Otol Rhinol Laryngol 112:298\u2013302","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"2118_CR41","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1080\/00016480310016893","volume":"124","author":"Hafkamp","year":"2004","unstructured":"Hafkamp HC, Manni JJ, Speel EJ (2004) Role of human papillomavirus in the development of head and neck squamous cell carcinomas. Acta Otolaryngol 124:520\u2013526","journal-title":"Acta Otolaryngol"},{"key":"2118_CR42","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(09)61045-X","volume":"373","author":"Harper","year":"2009","unstructured":"Harper DM (2009) Preliminary HPV vaccine results for women older than 25\u00a0years. Lancet 373:1921\u20131922","journal-title":"Lancet"},{"key":"2118_CR43","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","volume":"364","author":"Harper","year":"2004","unstructured":"Harper DM, Franco EL, Wheeler C et al (2004) Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364:1757\u20131765","journal-title":"Lancet"},{"key":"2118_CR44","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","volume":"367","author":"Harper","year":"2006","unstructured":"Harper DM, Franco EL, Wheeler CM et al (2006) Sustained efficacy up to 4.5\u00a0years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367:1247\u20131255","journal-title":"Lancet"},{"key":"2118_CR45","doi-asserted-by":"crossref","unstructured":"Hepburn HM, Kaufmann AM (2009) Nobel price for vaccination against cervical cancer: current data and guidelines. Internist (Berl) 50:617\u2013626","DOI":"10.1007\/s00108-009-2388-9"},{"key":"2118_CR46","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.298.7.743","volume":"298","author":"Hildesheim","year":"2007","unstructured":"Hildesheim A, Herrero R, Wacholder S et al (2007) Effect of human papillomavirus 16\/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 298:743\u2013753","journal-title":"JAMA"},{"key":"2118_CR47","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1749-4486.2006.01246.x","volume":"31","author":"Hobbs","year":"2006","unstructured":"Hobbs CG, Sterne JA, Bailey M et al (2006) Human papillomavirus and head and neck cancer: a systematic review and meta-analysis. Clin Otolaryngol 31:259\u2013266","journal-title":"Clin Otolaryngol"},{"key":"2118_CR48","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/ijc.21565","volume":"118","author":"Hoffmann","year":"2006","unstructured":"Hoffmann TK, Arsov C, Schirlau K et al (2006) T cells specific for HPV\u00a016 E7 epitopes in patients with squamous cell carcinoma of the oropharynx. Int J Cancer 118:1984\u20131991","journal-title":"Int J Cancer"},{"key":"2118_CR49","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0002-9440(10)63871-0","volume":"162","author":"Klussmann","year":"2003","unstructured":"Klussmann JP, Gultekin E, Weissenborn SJ et al (2003) Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol 162:747\u2013753","journal-title":"Am J Pathol"},{"key":"2118_CR50","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00106-008-1867-y","volume":"57","author":"Klussmann","year":"2009","unstructured":"Klussmann JP, Preuss SF, Speel EJ (2009) Humane Papillomviren und Oropharynxkarzinome: Molekulare Interaktion und klinische Auswirkung. HNO 57:113\u2013122","journal-title":"HNO"},{"key":"2118_CR51","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0002-9343(97)00177-0","volume":"102","author":"Koutsky","year":"1997","unstructured":"Koutsky L (1997) Epidemiology of genital human papillomavirus infection. Am J Med 102:3\u20138","journal-title":"Am J Med"},{"key":"2118_CR52","doi-asserted-by":"crossref","unstructured":"Koutsky LA, Ault KA, Wheeler CM et al; Proof of Principle Study Investigators (2002) A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 347:1645\u20131651","DOI":"10.1056\/NEJMoa020586"},{"key":"2118_CR53","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1086\/381504","volume":"189","author":"Kreimer","year":"2004","unstructured":"Kreimer AR, Alberg AJ, Daniel R et al (2004) Oral human papillomavirus infection in adults is associated with sexual behavior and HIV serostatus. J Infect Dis 189:686\u2013698","journal-title":"J Infect Dis"},{"key":"2118_CR54","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1158\/1055-9965.EPI-04-0551","volume":"14","author":"Kreimer","year":"2005","unstructured":"Kreimer AR, Clifford GM, Boyle P et al (2005) Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 14:467\u2013475","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2118_CR55","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1158\/1078-0432.CCR-04-0054","volume":"10","author":"Kuss","year":"2004","unstructured":"Kuss I, Hathaway B, Ferris RL et al (2004) Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res 10:3755\u20133762","journal-title":"Clin Cancer Res"},{"key":"2118_CR56","first-page":"161","volume":"62","author":"Kuss","year":"2005","unstructured":"Kuss I, Hathaway B, Ferris RL et al (2005) Imbalance in absolute counts of T lymphocyte subsets in patients with head and neck cancer and its relation to disease. Adv Otorhinolaryngol 62:161\u2013172","journal-title":"Adv Otorhinolaryngol"},{"key":"2118_CR57","doi-asserted-by":"crossref","first-page":"5630","DOI":"10.1200\/JCO.2005.04.6136","volume":"24","author":"Licitra","year":"2006","unstructured":"Licitra L, Perrone F, Bossi P et al (2006) High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 24:5630\u20135636","journal-title":"J Clin Oncol"},{"key":"2118_CR58","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1365-2273.1986.tb00146.x","volume":"11","author":"Lindeberg","year":"1986","unstructured":"Lindeberg H, Oster S, Oxlund I et al (1986) Laryngeal papillomas: classification and course. Clin Otolaryngol Allied Sci 11:423\u2013429","journal-title":"Clin Otolaryngol Allied Sci"},{"key":"2118_CR59","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/01.olq.0000204545.89516.0a","volume":"33","author":"Manhart","year":"2006","unstructured":"Manhart LE, Holmes KK, Koutsky LA et al (2006) Human papillomavirus infection among sexually active young women in the United States: Implications for developing a vaccination strategy. Sex Transm Dis 33:502\u2013508","journal-title":"Sex Transm Dis"},{"key":"2118_CR60","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/01.AOG.0000192397.41191.fb","volume":"107","author":"Mao","year":"2006","unstructured":"Mao C, Koutsky LA, Ault KA et al (2006) Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 107:18-27","journal-title":"Obstet Gynecol"},{"key":"2118_CR61","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJM199306173282412","volume":"328","author":"Mashberg","year":"1993","unstructured":"Mashberg A (1993) Head and neck cancer. N Engl J Med 328:1783; author reply 1784","journal-title":"N Engl J Med"},{"key":"2118_CR62","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1002\/ijc.22894","volume":"121","author":"Molling","year":"2007","unstructured":"Molling JW, De Gruijl TD, Glim J et al (2007) CD4(+)CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia. Int J Cancer 121:1749\u20131755","journal-title":"Int J Cancer"},{"key":"2118_CR63","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJM200104123441503","volume":"344","author":"Mork","year":"2001","unstructured":"Mork J, Lie AK, Glattre E et al (2001) Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 344:1125\u20131131","journal-title":"N Engl J Med"},{"key":"2118_CR64","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0022-3476(98)70445-7","volume":"132","author":"Moscicki","year":"1998","unstructured":"Moscicki AB, Shiboski S, Broering J et al (1998) The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 132:277\u2013284","journal-title":"J Pediatr"},{"key":"2118_CR65","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa021641","volume":"348","author":"Munoz","year":"2003","unstructured":"Munoz N, Bosch FX, De Sanjose S et al (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518\u2013527","journal-title":"N Engl J Med"},{"key":"2118_CR66","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","volume":"369","author":"Paavonen","year":"2007","unstructured":"Paavonen J, Jenkins D, Bosch FX et al (2007) Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369:2161\u20132170","journal-title":"Lancet"},{"key":"2118_CR67","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","volume":"55","author":"Parkin","year":"2005","unstructured":"Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74\u2013108","journal-title":"CA Cancer J Clin"},{"key":"2118_CR68","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.1016\/j.vaccine.2009.03.086","volume":"27","author":"Pathirana","year":"2009","unstructured":"Pathirana D, Hillemanns P, Petry KU et al (2009) Short version of the German evidence-based guidelines for prophylactic vaccination against HPV-associated neoplasia. Vaccine 27:4551\u20134559","journal-title":"Vaccine"},{"key":"2118_CR69","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.1055\/s-0029-1220219","volume":"134","author":"Pawlita","year":"2009","unstructured":"Pawlita M, Gissmann L (2009) Recurrent respiratory papillomatosis: indication for HPV vaccination? Dtsch Med Wochenschr 134(Suppl 2):S100\u2013S102","journal-title":"Dtsch Med Wochenschr"},{"key":"2118_CR70","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1002\/(SICI)1097-0142(19990501)85:9<1903::AID-CNCR4>3.0.CO;2-6","volume":"85","author":"Pintos","year":"1999","unstructured":"Pintos J, Franco EL, Black MJ et al (1999) Human papillomavirus and prognoses of patients with cancers of the upper aerodigestive tract. Cancer 85:1903\u20131909","journal-title":"Cancer"},{"key":"2118_CR71","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1002\/ijc.22355","volume":"120","author":"Reimers","year":"2007","unstructured":"Reimers N, Kasper HU, Weissenborn SJ et al (2007) Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer 120:1731\u20131738","journal-title":"Int J Cancer"},{"key":"2118_CR72","first-page":"485","volume":"12","author":"Richardson","year":"2003","unstructured":"Richardson H, Kelsall G, Tellier P et al (2003) The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev 12:485\u2013490","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2118_CR73","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1365-2273.1993.tb00616.x","volume":"18","author":"Rihkanen","year":"1993","unstructured":"Rihkanen H, Aaltonen LM, Syrjanen SM (1993) Human papillomavirus in laryngeal papillomas and in adjacent normal epithelium. Clin Otolaryngol Allied Sci 18:470\u2013474","journal-title":"Clin Otolaryngol Allied Sci"},{"key":"2118_CR74","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/ijc.10960","volume":"104","author":"Ritchie","year":"2003","unstructured":"Ritchie JM, Smith EM, Summersgill KF et al (2003) Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx. Int J Cancer 104:336\u2013344","journal-title":"Int J Cancer"},{"key":"2118_CR75","unstructured":"Robert-Koch-Institut (2009) Impfung gegen HPV \u2013 Aktuelle Bewertung der STIKO. Epidemiologisches Bulletin 32\/09. http:\/\/www.rki.de\/cln_153\/nn_1378492\/DE\/Content\/Infekt\/EpidBull\/Archiv\/2009\/32__09,templateId=raw,property=publicationFile.pdf\/32_09.pdf:319\u2013328"},{"key":"2118_CR76","unstructured":"Robert-Koch-Institut (2007) Impfung gegen humane Papillomaviren (HPV) f\u00fcr M\u00e4dchen und Frauen von 12 bis 17\u00a0Jahren \u2013 Empfehlung und Begr\u00fcndung. Epidemiologisches Bulletin 12\/07. http:\/\/www.rki.de\/cln_153\/nn_264978\/DE\/Content\/Infekt\/EpidBull\/Archiv\/2007\/12__07.html?__nnn=true:97\u2013103"},{"key":"2118_CR77","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/sj.bjc.6602407","volume":"92","author":"Schaefer","year":"2005","unstructured":"Schaefer C, Kim GG, Albers A et al (2005) Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer 92:913\u2013920","journal-title":"Br J Cancer"},{"key":"2118_CR78","doi-asserted-by":"crossref","unstructured":"Schiffman M, Kjaer SK (2003) Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 14\u201319","DOI":"10.1093\/oxfordjournals.jncimonographs.a003476"},{"key":"2118_CR79","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1093\/jnci\/djg037","volume":"95","author":"Schlecht","year":"2003","unstructured":"Schlecht NF, Platt RW, Duarte-Franco E et al (2003) Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst 95:1336\u20131343","journal-title":"J Natl Cancer Inst"},{"key":"2118_CR80","unstructured":"Schneider A, Koutsky LA (1992) Natural history and epidemiological features of genital HPV infection. IARC Sci Publ 25\u201352"},{"key":"2118_CR81","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1093\/jnci\/90.21.1626","volume":"90","author":"Schwartz","year":"1998","unstructured":"Schwartz SM, Daling JR, Doody DR et al (1998) Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. J Natl Cancer Inst 90:1626\u20131636","journal-title":"J Natl Cancer Inst"},{"key":"2118_CR82","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1586\/14760584.7.10.1465","volume":"7","author":"Schwarz","year":"2008","unstructured":"Schwarz TF (2008) AS04-adjuvanted human papillomavirus-16\/18 vaccination: recent advances in cervical cancer prevention. Expert Rev Vaccines 7:1465\u20131473","journal-title":"Expert Rev Vaccines"},{"key":"2118_CR83","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/INF.0b013e318149dfea","volume":"26","author":"Siegrist","year":"2007","unstructured":"Siegrist CA, Lewis EM, Eskola J et al (2007) Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions. Pediatr Infect Dis J 26:979\u2013984","journal-title":"Pediatr Infect Dis J"},{"key":"2118_CR84","first-page":"59","volume":"2","author":"Sillman","year":"1997","unstructured":"Sillman FH, Sentovich S, Shaffer D (1997) Ano-genital neoplasia in renal transplant patients. Ann Transplant 2:59\u201366","journal-title":"Ann Transplant"},{"key":"2118_CR85","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/jnci\/djh074","volume":"96","author":"Smith","year":"2004","unstructured":"Smith EM, Ritchie JM, Summersgill KF et al (2004) Human papillomavirus in oral exfoliated cells and risk of head and neck cancer. J Natl Cancer Inst 96:449\u2013455","journal-title":"J Natl Cancer Inst"},{"key":"2118_CR86","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/ijc.11633","volume":"108","author":"Smith","year":"2004","unstructured":"Smith EM, Ritchie JM, Summersgill KF et al (2004) Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers. Int J Cancer 108:766\u2013772","journal-title":"Int J Cancer"},{"key":"2118_CR87","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1177\/000348940010901114","volume":"109","author":"Smith","year":"2000","unstructured":"Smith EM, Summersgill KF, Allen J et al (2000) Human papillomavirus and risk of laryngeal cancer. Ann Otol Rhinol Laryngol 109:1069\u20131076","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"2118_CR88","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1046\/j.1365-2230.2002.01151.x","volume":"27","author":"Stanley","year":"2002","unstructured":"Stanley MA (2002) Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol 27:571\u2013577","journal-title":"Clin Exp Dermatol"},{"key":"2118_CR89","doi-asserted-by":"crossref","first-page":"6301","DOI":"10.1158\/1078-0432.CCR-07-1403","volume":"13","author":"Strauss","year":"2007","unstructured":"Strauss L, Bergmann C, Gooding W et al (2007) The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 13:6301\u20136311","journal-title":"Clin Cancer Res"},{"key":"2118_CR90","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/j.jcv.2004.11.017","volume":"32","author":"Syrjanen","year":"2005","unstructured":"Syrjanen S (2005) Human papillomavirus (HPV) in head and neck cancer. J Clin Virol 32(Suppl 1):S59\u2013S66","journal-title":"J Clin Virol"},{"key":"2118_CR91","first-page":"475","volume":"93","author":"Tenti","year":"1999","unstructured":"Tenti P, Zappatore R, Migliora P et al (1999) Perinatal transmission of human papillomavirus from gravidas with latent infections. Obstet Gynecol 93:475\u2013479","journal-title":"Obstet Gynecol"},{"key":"2118_CR92","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ygyno.2004.08.052","volume":"96","author":"Valdespino","year":"2005","unstructured":"Valdespino V, Gorodezky C, Ortiz V et al (2005) HPV\u00a016-specific cytotoxic T lymphocyte responses are detected in all HPV\u00a016-positive cervical cancer patients. Gynecol Oncol 96:92\u2013102","journal-title":"Gynecol Oncol"},{"key":"2118_CR93","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1006\/clim.2001.5094","volume":"101","author":"Vambutas","year":"2001","unstructured":"Vambutas A, Devoti J, Pinn W et al (2001) Interaction of human papillomavirus type 11 E7 protein with TAP-1 results in the reduction of ATP-dependent peptide transport. Clin Immunol 101:94\u201399","journal-title":"Clin Immunol"},{"key":"2118_CR94","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/ijc.21394","volume":"118","author":"Van","year":"2006","unstructured":"Van Poelgeest MI, Nijhuis ER, Kwappenberg KM et al (2006) Distinct regulation and impact of type 1 T-cell immunity against HPV\u00a016 L1, E2 and E6 antigens during HPV\u00a016-induced cervical infection and neoplasia. Int J Cancer 118:675\u2013683","journal-title":"Int J Cancer"},{"key":"2118_CR95","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1016\/j.vaccine.2006.04.068","volume":"24","author":"Villa","year":"2006","unstructured":"Villa LL, Ault KA, Giuliano AR et al (2006) Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16 and 18. Vaccine 24:5571\u20135583","journal-title":"Vaccine"},{"key":"2118_CR96","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(05)70101-7","volume":"6","author":"Villa","year":"2005","unstructured":"Villa LL, Costa RL, Petta CA et al (2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6:271\u2013278","journal-title":"Lancet Oncol"},{"key":"2118_CR97","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1093\/jnci\/dji428","volume":"97","author":"Vinokurova","year":"2005","unstructured":"Vinokurova S, Wentzensen N, Einenkel J et al (2005) Clonal history of papillomavirus-induced dysplasia in the female lower genital tract. J Natl Cancer Inst 97:1816\u20131821","journal-title":"J Natl Cancer Inst"},{"key":"2118_CR98","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1158\/1055-9965.EPI-03-0166","volume":"13","author":"Viscidi","year":"2004","unstructured":"Viscidi RP, Schiffman M, Hildesheim A et al (2004) Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev 13:324\u2013327","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2118_CR99","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1056\/NEJM199301213280306","volume":"328","author":"Vokes","year":"1993","unstructured":"Vokes EE, Weichselbaum RR, Lippman SM et al (1993) Head and neck cancer. N Engl J Med 328:184\u2013194","journal-title":"N Engl J Med"},{"key":"2118_CR100","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","volume":"189","author":"Walboomers","year":"1999","unstructured":"Walboomers JM, Jacobs MV, Manos MM et al (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12\u201319","journal-title":"J Pathol"},{"key":"2118_CR101","first-page":"636","volume":"63","author":"Welters","year":"2003","unstructured":"Welters MJ, De Jong A, Van Den Eeden SJ et al (2003) Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. Cancer Res 63:636\u2013641","journal-title":"Cancer Res"},{"key":"2118_CR102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.mlg.000148224.83491.0f","volume":"114","author":"Wiatrak","year":"2004","unstructured":"Wiatrak BJ, Wiatrak DW, Broker TR et al (2004) Recurrent respiratory papillomatosis: a longitudinal study comparing severity associated with human papilloma viral types 6 and 11 and other risk factors in a large pediatric population. Laryngoscope 114:1\u201323","journal-title":"Laryngoscope"},{"key":"2118_CR103","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/(SICI)1097-0215(20000201)85:3<313::AID-IJC3>3.0.CO;2-W","volume":"85","author":"Zumbach","year":"2000","unstructured":"Zumbach K, Kisseljov F, Sacharova O et al (2000) Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in cervical-carcinoma patients from Russia. Int J Cancer 85:313\u2013318","journal-title":"Int J Cancer"},{"key":"2118_CR104","first-page":"252","volume":"93","author":"Zur","year":"2001","unstructured":"Zur Hausen H (2001) Cervical carcinoma and human papillomavirus: on the road to preventing a major human cancer. J Natl Cancer Inst 93:252\u2013253","journal-title":"J Natl Cancer Inst"},{"key":"2118_CR105","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nrc798","volume":"2","author":"Zur","year":"2002","unstructured":"Zur Hausen H (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2:342\u2013350","journal-title":"Nat Rev Cancer"},{"key":"2118_CR106","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0264-410X(02)00599-6","volume":"21","author":"Adams","year":"2003","unstructured":"Adams M, Navabi H, Jasani B et al. (2003) Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C(12)U] (Ampligen R). Vaccine 21:787-790","journal-title":"Vaccine"},{"key":"2118_CR107","first-page":"5205","volume":"9","author":"Baldwin","year":"2003","unstructured":"Baldwin PJ, van der Burg SH, Boswell CM et al. (2003) Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Clin Cancer Res 9:5205-5213","journal-title":"Clin Cancer Res"},{"key":"2118_CR108","doi-asserted-by":"crossref","first-page":"s333","DOI":"10.2741\/1003","volume":"8","author":"Berry","year":"2003","unstructured":"Berry JM, Palefsky JM (2003) A review of human papillomavirus vaccines: from basic science to clinical trials. Front Biosci 8:s333-345","journal-title":"Front Biosci"},{"key":"2118_CR109","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/S0140-6736(96)90674-1","volume":"347","author":"Borysiewicz","year":"1996","unstructured":"Borysiewicz LK, Fiander A, Nimako M et al. (1996) A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 347:1523-1527","journal-title":"Lancet"},{"key":"2118_CR110","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1089\/104303402753812520","volume":"13","author":"Corona","year":"2002","unstructured":"Corona Gutierrez CM, Tinoco A, Lopez Contreras M et al. (2002) Clinical protocol. A phase II study: efficacy of the gene therapy of the MVA E2 recombinant virus in the treatment of precancerous lesions (NIC I and NIC II) associated with infection of oncogenic human papillomavirus. Hum Gene Ther 13:1127-1140","journal-title":"Hum Gene Ther"},{"key":"2118_CR111","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1089\/10430340460745757","volume":"15","author":"Corona","year":"2004","unstructured":"Corona Gutierrez CM, Tinoco A, Navarro T et al. (2004) Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. Hum Gene Ther 15:421-431","journal-title":"Hum Gene Ther"},{"key":"2118_CR112","first-page":"6032","volume":"63","author":"Davidson","year":"2003","unstructured":"Davidson EJ, Boswell CM, Sehr P et al. (2003) Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16\/18 oncoproteins. Cancer Res 63:6032-6041","journal-title":"Cancer Res"},{"key":"2118_CR113","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1016\/j.vaccine.2004.01.049","volume":"22","author":"Davidson","year":"2004","unstructured":"Davidson EJ, Faulkner RL, Sehr P et al. (2004) Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16\/18 E6E7). Vaccine 22:2722-2729","journal-title":"Vaccine"},{"key":"2118_CR114","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1016\/S0264-410X(02)00350-X","volume":"20","author":"De","year":"2002","unstructured":"De Jong A, O\u2019Neill T, Khan AY et al. (2002) Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine 20:3456-3464","journal-title":"Vaccine"},{"key":"2118_CR115","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ygyno.2007.04.038","volume":"106","author":"Einstein","year":"2007","unstructured":"Einstein MH, Kadish AS, Burk RD et al. (2007) Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III. Gynecol Oncol 106:453-460","journal-title":"Gynecol Oncol"},{"key":"2118_CR116","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00432-003-0463-5","volume":"129","author":"Ferrara","year":"2003","unstructured":"Ferrara A, Nonn M, Sehr P et al. (2003) Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. J Cancer Res Clin Oncol 129:521-530","journal-title":"J Cancer Res Clin Oncol"},{"key":"2118_CR117","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/j.1525-1438.2006.00598.x","volume":"16","author":"Fiander","year":"2006","unstructured":"Fiander AN, Tristram AJ, Davidson EJ et al. (2006) Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial. Int J Gynecol Cancer 16:1075-1081","journal-title":"Int J Gynecol Cancer"},{"key":"2118_CR118","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.vaccine.2004.05.013","volume":"23","author":"Frazer","year":"2004","unstructured":"Frazer IH, Quinn M, Nicklin JL et al. (2004) Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. Vaccine 23:172-181","journal-title":"Vaccine"},{"key":"2118_CR119","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1600-065X.1999.tb01288.x","volume":"168","author":"Frazer","year":"1999","unstructured":"Frazer IH, Thomas R, Zhou J et al. (1999) Potential strategies utilised by papillomavirus to evade host immunity. Immunol Rev 168:131-142","journal-title":"Immunol Rev"},{"key":"2118_CR120","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/01.AOG.0000110246.93627.17","volume":"103","author":"Garcia","year":"2004","unstructured":"Garcia F, Petry KU, Muderspach L et al. (2004) ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 103:317-326","journal-title":"Obstet Gynecol"},{"key":"2118_CR121","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s10350-004-6229-6","volume":"45","author":"Goldstone","year":"2002","unstructured":"Goldstone SE, Palefsky JM, Winnett MT et al. (2002) Activity of HspE7, a novel immunotherapy, in patients with anogenital warts. Dis Colon Rectum 45:502-507","journal-title":"Dis Colon Rectum"},{"key":"2118_CR122","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s00262-004-0501-4","volume":"53","author":"Hallez","year":"2004","unstructured":"Hallez S, Simon P, Maudoux F et al. (2004) Phase I\/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia. Cancer Immunol Immunother 53:642-650","journal-title":"Cancer Immunol Immunother"},{"key":"2118_CR123","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","volume":"364","author":"Harper","year":"2004","unstructured":"Harper DM, Franco EL, Wheeler C et al. (2004) Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364:1757-1765","journal-title":"Lancet"},{"key":"2118_CR124","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","volume":"367","author":"Harper","year":"2006","unstructured":"Harper DM, Franco EL, Wheeler CM et al. (2006) Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367:1247-1255","journal-title":"Lancet"},{"key":"2118_CR125","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1002\/ijc.23022","volume":"121","author":"Kaufmann","year":"2007","unstructured":"Kaufmann AM, Nieland JD, Jochmus I et al. (2007) Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2\/3). Int J Cancer 121:2794-2800","journal-title":"Int J Cancer"},{"key":"2118_CR126","first-page":"3676","volume":"8","author":"Kaufmann","year":"2002","unstructured":"Kaufmann AM, Stern PL, Rankin EM et al. (2002) Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res 8:3676-3685","journal-title":"Clin Cancer Res"},{"key":"2118_CR127","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1016\/S0264-410X(03)00454-7","volume":"21","author":"Kawana","year":"2003","unstructured":"Kawana K, Yasugi T, Kanda T et al. (2003) Safety and immunogenicity of a peptide containing the cross-neutralization epitope of HPV16 L2 administered nasally in healthy volunteers. Vaccine 21:4256-4260","journal-title":"Vaccine"},{"key":"2118_CR128","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1158\/1078-0432.CCR-07-1881","volume":"14","author":"Kenter","year":"2008","unstructured":"Kenter GG, Welters MJ, Valentijn AR et al. (2008) Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res 14:169-177","journal-title":"Clin Cancer Res"},{"key":"2118_CR129","first-page":"1028","volume":"8","author":"Klencke","year":"2002","unstructured":"Klencke B, Matijevic M, Urban RG et al. (2002) Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin Cancer Res 8:1028-1037","journal-title":"Clin Cancer Res"},{"key":"2118_CR130","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1086\/314616","volume":"179","author":"Lacey","year":"1999","unstructured":"Lacey CJ, Thompson HS, Monteiro EF et al. (1999) Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts. J Infect Dis 179:612-618","journal-title":"J Infect Dis"},{"key":"2118_CR131","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/01.AOG.0000192397.41191.fb","volume":"107","author":"Mao","year":"2006","unstructured":"Mao C, Koutsky LA, Ault KA et al. (2006) Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 107:18-27","journal-title":"Obstet Gynecol"},{"key":"2118_CR132","first-page":"3406","volume":"6","author":"Muderspach","year":"2000","unstructured":"Muderspach L, Wilczynski S, Roman L et al. (2000) A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 6:3406-3416","journal-title":"Clin Cancer Res"},{"key":"2118_CR133","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1097\/01.aids.0000226955.02719.26","volume":"20","author":"Palefsky","year":"2006","unstructured":"Palefsky JM, Berry JM, Jay N et al. (2006) A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals. AIDS 20:1151-1155","journal-title":"AIDS"},{"key":"2118_CR134","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00002371-200003000-00010","volume":"23","author":"Ressing","year":"2000","unstructured":"Ressing ME, Van Driel WJ, Brandt RM et al. (2000) Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J Immunother 23:255-266","journal-title":"J Immunother"},{"key":"2118_CR135","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ygyno.2007.05.038","volume":"106","author":"Roman","year":"2007","unstructured":"Roman LD, Wilczynski S, Muderspach LI et al. (2007) A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia. Gynecol Oncol 106:558-566","journal-title":"Gynecol Oncol"},{"key":"2118_CR136","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1056\/NEJM200205303462219","volume":"346","author":"Santin","year":"2002","unstructured":"Santin AD, Bellone S, Gokden M et al. (2002) Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer. N Engl J Med 346:1752-1753","journal-title":"N Engl J Med"},{"key":"2118_CR137","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1128\/JVI.02343-07","volume":"82","author":"Santin","year":"2008","unstructured":"Santin AD, Bellone S, Palmieri M et al. (2008) Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. J Virol 82:1968-1979","journal-title":"J Virol"},{"key":"2118_CR138","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1067\/mob.2003.256","volume":"188","author":"Sheets","year":"2003","unstructured":"Sheets EE, Urban RG, Crum CP et al. (2003) Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. Am J Obstet Gynecol 188:916-926","journal-title":"Am J Obstet Gynecol"},{"key":"2118_CR139","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1158\/1078-0432.CCR-03-0703","volume":"10","author":"Smyth","year":"2004","unstructured":"Smyth LJ, Van Poelgeest MI, Davidson EJ et al. (2004) Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin Cancer Res 10:2954-2961","journal-title":"Clin Cancer Res"},{"key":"2118_CR140","first-page":"2103","volume":"4","author":"Steller","year":"1998","unstructured":"Steller MA, Gurski KJ, Murakami M et al. (1998) Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin Cancer Res 4:2103-2109","journal-title":"Clin Cancer Res"},{"key":"2118_CR141","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0264-410X(98)00146-7","volume":"17","author":"Thompson","year":"1999","unstructured":"Thompson HS, Davies ML, Holding FP et al. (1999) Phase I safety and antigenicity of TA-GW: a recombinant HPV6 L2E7 vaccine for the treatment of genital warts. Vaccine 17:40-49","journal-title":"Vaccine"},{"key":"2118_CR142","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0889-8588(05)70164-7","volume":"13","author":"Van","year":"1999","unstructured":"Van Driel WJ, Kenter GG, Fleuren GJ et al. (1999) Immunotherapeutic strategies for cervical squamous carcinoma. Hematol Oncol Clin North Am 13:259-273","journal-title":"Hematol Oncol Clin North Am"},{"key":"2118_CR143","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1086\/498164","volume":"192","author":"Vandepapeliere","year":"2005","unstructured":"Vandepapeliere P, Barrasso R, Meijer CJ et al. (2005) Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination. J Infect Dis 192:2099-2107","journal-title":"J Infect Dis"},{"key":"2118_CR144","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(05)70101-7","volume":"6","author":"Villa","year":"2005","unstructured":"Villa LL, Costa RL, Petta CA et al. (2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6:271-278","journal-title":"Lancet Oncol"}],"container-title":["HNO"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00106-010-2118-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00106-010-2118-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00106-010-2118-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T03:55:37Z","timestamp":1558583737000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00106-010-2118-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,12]]},"references-count":144,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["2118"],"URL":"https:\/\/doi.org\/10.1007\/s00106-010-2118-6","relation":{},"ISSN":["0017-6192","1433-0458"],"issn-type":[{"value":"0017-6192","type":"print"},{"value":"1433-0458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,12]]}}}